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teristics that predict post-transplant recurrence’’ [7]. It is not
known yet if LRTs represent per se a surrogate of tumor biology
or if LRT works only through the proof of time. On this scope,
we recently demonstrated that ‘‘fast track’’ LT does not allow to
time the selection patients according to tumor aggressiveness [8].
We recognize some limitations. Both the studies by Otto et al.
and Lai et al. did not investigate the effect of LRT on the dropout
during waiting-time. However, an ongoing analysis performed on
821 patients coming from the EurHeCaLT study group further
conﬁrmed the role of radiological progression as selection tool
in terms of drop-out rate [9].
Secondarily, CT scans older than 5 years are not always well
evaluated by mRECIST criteria.
In conclusion, waiting for reliable preoperative predictive
markers of both adverse outcome and response to pretransplant
treatment [10], morphologic criteria remain the giants in the
evaluation of LT candidates. Biological criteria still are the dwarfs.
However, when dwarfs climb the shoulders of giants, they have
the chance to see far, allowing longer survivals.
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Letters to the EditorTo the Editor:
I thank Dr. Lai for his letter stressing some important issues of
our recent publication [1]. With great interest I have recognized1332 Journal of Hepatology 2014
Open access under CC BY-NC-ND license.that Dr. Lai’s analysis of the EurHeCaLT data endorse the princi-
ples of our statements in a much greater cohort of patients [2].
We have focussed on response of hepatocellular carcinomasvol. 60 j 1325–1333
(HCC) to trans-arterial chemoembolization (TACE) during pre-
treatment before liver transplantation. Lai et al. have, in addition,
included alpha fetoprotein to assess another biological tumour
characteristic. The drop-out rate (in our experience 40%) was nei-
ther in our, nor in the EurHeCaLT study an issue.
As we participate in the EurHeCaLT working group, we dare to
point out some differences in the clinical practice of the group
members. In our patients, TACE was always repeatedly performed
and other approaches to pre-treatment have not been included in
our analysis. Considering all differences of the EurHeCaLT group
members, the similarity of the results is remarkable: regardless
if the HCC met or exceeded the Milan Criteria, putative surrogates
of tumour biology are predictors for tumour recurrence. This
issue deserves consideration, not only since the characterization
of tumour size and number still remains a clinical problem [3].
Indeed, the results corroborate that ‘‘size and number tell only
a partial tale of the tumour characteristics’’ [4].
Dr. Lai’s sentence ‘‘. . .waiting for reliable preoperative
predictive markers of both adverse outcome and response to
pre-transplant treatment. . .’’ should not be misunderstood! In
my understanding – and I suppose we share this opinion –
drop-out and recurrence are two sides of the same coin: tumour
biology. Although there is no ﬁnal proof, biologically aggressive
HCCs appear to be refractory to TACE and entail, accordingly, a
higher recurrence rate after transplantation. Likewise, multifocal
‘‘recurrence’’ immediately following surgery or radiofrequency
ablation may also reﬂect biological aggressiveness and the out-
come is poor. What we do not know is, if one of the approaches
to pre-treatment is more accurate in selecting appropriate
patients than the other [5].
Is the selection process ensuing from pre-treatment just proof
for an extended time axis? The number of pre-transplant TACE
procedures – which parallels waiting time – did not impact recur-
rence in our study. Response, but not time appeared to be crucial.
In a few patients, however, tumours were initially stable or
exhibited even partial response and progressed later despite
ongoing pre-treatment. Therefore, time may be of importance.
As long as we don’t have reliable markers reﬂecting tumour
biology we should aim, at least, at reinforcing the existing data
to improve the selection of HCC patients amenable to liver trans-
plantation. Transplant centres should be invited to participate in
a multicentre study seizing the principles of pre-transplant treat-
ment of the EurHeCaLT members but pre-treatment should be
uniform. Finally, allowme a brief remark that should not be taken
too seriously. I would like to reverse Dr. Lai’s nice picture describ-
ing the giant and the dwarf: tumour biology is the giant – and the
dwarf ‘‘morphology’’ will hopefully start descending from the
giant’s shoulders.
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